High-affinity immunoglobulin epsilon receptor (FcεRI) and Immunoglobulin E (IgE) (IgE-FcεRI)

The High-affinity immunoglobulin epsilon receptor (FcεRI) and Immunoglobulin E (IgE) complex is the central mediator of Type I hypersensitivity and allergic inflammation (StatPearls: NBK513315). IgE antibodies, produced by B cells, bind via their Fc region to the alpha subunit of the FcεRI receptor (UniProt: P12319) found predominantly on mast cells and basophils. Upon exposure to a specific allergen, the receptor-bound IgE molecules are cross-linked, triggering an intracellular signaling cascade that results in the degranulation and release of potent inflammatory mediators such as histamine, proteases, and leukotrienes (PubMed: 29307316). This physiological process is the primary driver of clinical symptoms in diseases like allergic asthma, allergic rhinitis, and chronic spontaneous urticaria. Therapeutic strategies, exemplified by the monoclonal antibody omalizumab, target this pathway by binding to free IgE at the same site used for receptor interaction, effectively neutralizing the antibody and preventing the activation of mast cells and basophils (PubMed: 12756242). By reducing the concentration of free IgE, these therapies also lead to a secondary downregulation of FcεRI expression on effector cells, further dampening the allergic response. This target complex remains a cornerstone of precision medicine in immunology, with newer agents aiming for higher affinity or different epitopes to improve clinical outcomes in refractory patients.

Other names

Fc epsilon RIHigh affinity IgE receptorFceRIImmunoglobulin EIgE receptorFCER1AIGHEHuman IgE and IgE–FcεRI complex on mast cells and basophils

Monoclonal antibodies bind to the Cε3 domain of free circulating IgE, preventing its interaction with the FcεRI receptor on mast cells and basophils (PubMed: 12756242). This sequestration leads to a significant reduction in free IgE levels and a subsequent downregulation of FcεRI expression on the surface of effector cells, thereby inhibiting the release of inflammatory mediators (PubMed: 11486332).